Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
InMed Pharmaceuticals Inc. (INM) had Consolidated Net Income/Loss of $-1.73M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$1.12M |
|
$-1.73M |
|
$0.72M |
|
$0.40M |
|
$2.88M |
|
$-1.76M |
|
$0.04M |
|
$-1.73M |
|
$-1.73M |
|
$-1.73M |
|
$-1.73M |
|
|
Consolidated Net Income/Loss |
$-1.73M |
$-1.73M |
|
$-1.76M |
|
$-1.71M |
|
3.96M |
|
3.96M |
|
$-0.44 |
|
$-0.44 |
|
| Balance Sheet Financials | |
$10.80M |
|
$0.88M |
|
$2.56M |
|
$13.36M |
|
$1.55M |
|
$0.22M |
|
$0.22M |
|
$1.77M |
|
$11.59M |
|
$10.01M |
|
$11.59M |
|
2.60M |
|
| Cash Flow Statement Financials | |
$-1.61M |
|
$0.00M |
|
$-0.14M |
|
$11.08M |
|
$9.33M |
|
$-1.74M |
|
$0.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.95 |
|
-- |
|
-- |
|
0.02 |
|
0.06 |
|
35.99% |
|
-157.45% |
|
-157.45% |
|
-- |
|
-154.17% |
|
-154.17% |
|
$-1.61M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
0.80 |
|
3.26 |
|
27.60 |
|
-14.90% |
|
-17.25% |
|
-12.92% |
|
-14.63% |
|
$4.45 |
|
$-0.41 |
|
$-0.41 |
|